你想要点什么？个体修复能力对癌症基因毒性疗法疗效的影响。第二部分——抗癌治疗疗效评估中个体修复能力生物标志物的信息内容和有效性。
What's your poison? Impact of individual repair capacity on the outcomes of genotoxic therapies in cancer. Part II - information content and validity of biomarkers for individual repair capacity in the assessment of outcomes of anticancer therapy.
作者信息
Petkova Rumena, Chelenkova Pavlina, Georgieva Elena, Chakarov Stoian
机构信息
Scientific Technological Service (STS) , Sofia , Bulgaria.
Sofia University "St. Kliment Ohridski", Faculty of Biology , Sofia , Bulgaria.
出版信息
Biotechnol Biotechnol Equip. 2014 Jan 2;28(1):2-7. doi: 10.1080/13102818.2014.902532.
Abstract
The individual variance in the efficiency of repair of damage induced by genotoxic therapies may be an important factor in the assessment of eligibility for different anticancer treatments, the outcomes of various treatments and the therapy-associated complications, including acute and delayed toxicity and acquired drug resistance. The second part of this paper analyses the currently available information about the possibilities of using experimentally obtained knowledge about individual repair capacity for the purposes of personalised medicine and healthcare.
摘要
基因毒性疗法所诱导损伤的修复效率存在个体差异，这可能是评估不同抗癌治疗的适用性、各种治疗的结果以及治疗相关并发症（包括急性和迟发性毒性以及获得性耐药）的一个重要因素。本文的第二部分分析了目前可用的信息，这些信息涉及利用关于个体修复能力的实验性知识来实现个性化医疗和保健的可能性。
相似文献
1
What's your poison? Impact of individual repair capacity on the outcomes of genotoxic therapies in cancer. Part II - information content and validity of biomarkers for individual repair capacity in the assessment of outcomes of anticancer therapy.你想要点什么？个体修复能力对癌症基因毒性疗法疗效的影响。第二部分——抗癌治疗疗效评估中个体修复能力生物标志物的信息内容和有效性。
Biotechnol Biotechnol Equip. 2014 Jan 2;28(1):2-7. doi: 10.1080/13102818.2014.902532.
2
Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.DNA 修复靶向治疗的反应和耐药生物标志物。
Clin Cancer Res. 2016 Dec 1;22(23):5651-5660. doi: 10.1158/1078-0432.CCR-16-0247. Epub 2016 Sep 27.
3
Heritable and cancer risks of exposures to anticancer drugs: inter-species comparisons of covalent deoxyribonucleic acid-binding agents.接触抗癌药物的遗传风险和癌症风险：共价脱氧核糖核酸结合剂的种间比较
Mutat Res. 1998 May 25;400(1-2):509-40. doi: 10.1016/s0027-5107(98)00060-8.
4
Personal characteristics, therapy modalities and individual DNA repair capacity as predictive factors of acute skin toxicity in an unselected cohort of breast cancer patients receiving radiotherapy.个人特征、治疗方式及个体DNA修复能力作为接受放疗的未筛选乳腺癌患者急性皮肤毒性的预测因素
Radiother Oncol. 2003 Nov;69(2):145-53. doi: 10.1016/s0167-8140(03)00166-x.
5
Assessment of genotoxic effects related to chronic low level exposure to ionizing radiation using biomarkers for DNA damage and repair.使用DNA损伤与修复生物标志物评估与慢性低剂量电离辐射相关的遗传毒性效应。
Mutagenesis. 2002 May;17(3):223-32. doi: 10.1093/mutage/17.3.223.
6
Influence of genetic polymorphisms on biomarkers of exposure and genotoxic effects in styrene-exposed workers.遗传多态性对苯乙烯暴露工人暴露生物标志物和遗传毒性效应的影响。
Environ Mol Mutagen. 2004;44(4):293-303. doi: 10.1002/em.20069.
7
Relationship between the capacity to repair 8-oxoguanine, biomarkers of genotoxicity and individual susceptibility in styrene-exposed workers.苯乙烯暴露工人中8-氧代鸟嘌呤修复能力、遗传毒性生物标志物与个体易感性之间的关系。
Mutat Res. 2007 Dec 1;634(1-2):101-11. doi: 10.1016/j.mrgentox.2007.06.012. Epub 2007 Aug 9.
8
Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations.种系 TP53 突变背景下遗传毒性抗癌治疗与多原发肿瘤发生的相关性。
Eur J Cancer. 2018 Sep;101:254-262. doi: 10.1016/j.ejca.2018.06.011. Epub 2018 Jul 30.
9
Inherent and toxicant-provoked reduction in DNA repair capacity: A key mechanism for personalized risk assessment, cancer prevention and intervention, and response to therapy.内在的和毒物诱发的 DNA 修复能力降低：个性化风险评估、癌症预防和干预以及治疗反应的关键机制。
Int J Hyg Environ Health. 2018 Aug;221(7):993-1006. doi: 10.1016/j.ijheh.2018.07.003. Epub 2018 Jul 21.
10
[Dbait: An innovative concept to inhibit DNA repair and treat cancer].[Dbait：一种抑制DNA修复和治疗癌症的创新概念]
Bull Cancer. 2016 Mar;103(3):227-35. doi: 10.1016/j.bulcan.2016.01.007. Epub 2016 Feb 22.
引用本文的文献
1
Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.乳腺癌患者中5-氟尿嘧啶、多柔比星和环磷酰胺化疗毒性的药物遗传学
Oncotarget. 2018 Jan 10;9(10):9114-9136. doi: 10.18632/oncotarget.24148. eCollection 2018 Feb 6.
2
Deregulation of the circadian clock constitutes a significant factor in tumorigenesis: a clockwork cancer. Part II. studies.生物钟失调是肿瘤发生的一个重要因素：时钟机制与癌症。第二部分。研究。
Biotechnol Biotechnol Equip. 2014 May 4;28(3):379-386. doi: 10.1080/13102818.2014.925298. Epub 2014 Jul 24.
3
Stem cell application for osteoarthritis in the knee joint: A minireview.干细胞在膝关节骨关节炎中的应用：迷你综述。
World J Stem Cells. 2014 Nov 26;6(5):629-36. doi: 10.4252/wjsc.v6.i5.629.
本文引用的文献
1
ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.ERCC1 是局部晚期头颈部肿瘤的预后生物标志物：一项随机、Ⅱ期试验的结果。
Br J Cancer. 2013 Oct 15;109(8):2096-105. doi: 10.1038/bjc.2013.576. Epub 2013 Sep 24.
2
Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis.XPD基因多态性对非小细胞肺癌铂类化疗的预测价值：一项系统评价和荟萃分析
PLoS One. 2013 Aug 19;8(8):e72251. doi: 10.1371/journal.pone.0072251. eCollection 2013.
3
Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.ERCC1 C8092A 多态性可预测顺铂为基础的化疗治疗转移性/复发性鼻咽癌的无进展生存期。
Cancer Chemother Pharmacol. 2013 Aug;72(2):315-22. doi: 10.1007/s00280-013-2196-8. Epub 2013 May 28.
4
MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.MDM2 小分子拮抗剂 RG7112 激活 p53 信号通路并在临床前癌症模型中使人类肿瘤消退。
Cancer Res. 2013 Apr 15;73(8):2587-97. doi: 10.1158/0008-5472.CAN-12-2807. Epub 2013 Feb 11.
5
Excision repair of BPDE-adducts in human lymphocytes: diminished capacity associated with ERCC1 C8092A (rs3212986) polymorphism.人类淋巴细胞中 BPDE 加合物的切除修复：与 ERCC1 C8092A（rs3212986）多态性相关的能力降低。
Arch Toxicol. 2013 Apr;87(4):699-709. doi: 10.1007/s00204-012-0986-0. Epub 2012 Dec 1.
6
Implication of DNA repair genes in prostate tumourigenesis in Indian males.印度男性前列腺肿瘤发生中 DNA 修复基因的意义。
Indian J Med Res. 2012 Oct;136(4):622-32.
7
Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.TP53 和 MDM2 基因型与肉瘤治疗反应的相关性。
Cancer. 2013 Mar 1;119(5):1013-22. doi: 10.1002/cncr.27837. Epub 2012 Nov 16.
8
ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy.ATM 多态性可预测接受根治性放疗的非小细胞肺癌患者发生严重放射性肺炎的风险。
Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1066-73. doi: 10.1016/j.ijrobp.2012.09.024. Epub 2012 Nov 12.
9
The survival impact of XPA and XPC genetic polymorphisms on patients with esophageal squamous cell carcinoma.XPA 和 XPC 基因多态性对食管鳞癌患者生存的影响。
Ann Surg Oncol. 2013 Feb;20(2):562-71. doi: 10.1245/s10434-012-2622-x. Epub 2012 Sep 1.
10
Drug resistance in the mouse cancer clinic.小鼠癌症临床中的耐药性。
Drug Resist Updat. 2012 Feb-Apr;15(1-2):81-9. doi: 10.1016/j.drup.2012.01.001. Epub 2012 Feb 14.
Zotero 插件